Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported purchases exceed sales by $318.3MOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
Company profile
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Gloria Melanie | Chief Operating Officer | Aug 20 '26 | Sale | $44.16 | 3,056 | $134,953 | 219,301 | Aug 21 04:03 PM |
| Pande Atul | Director | Jul 24 '26 | Option Exercise | $8.43 | 1,500 | $12,645 | 118,231 | Jul 24 05:59 PM |
| Pande Atul | Director | Jul 24 '26 | Sale | $39.80 | 1,500 | $59,700 | 116,731 | Jul 24 05:59 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.